Researchers from Zhejiang University discovered a novel biomarker for acute myeloid leukemia

Acute myeloid leukemia is a malignancy of blood cells, and it is known as the most common type of leukemia in adults. Even after the successful treatment, the majority of patients’ health deteriorates after a period of improvement, with less than 30% of patients living 5 years after diagnosis.

Guided by the need to develop new prognostic biomarkers for this disease, researchers from the Department of Hematology of The First Affiliated Hospital, Zhejiang University School of Medicine discovered a novel gene signature, known as the ferroptosis related gene signature, that could be used for the prognosis of acute myeloid leukemia. This signature is based on the iron-dependent cell death mechanism, and researchers discovered 12 of them that correlate with patient overall survival.

Based on the presence of the ferroptosis gene signatures, patients were divided into high- and low-risk groups, with the high-risk group having these markers previously exhibited, which was proven to reduce overall survival in comparison to the low-risk group. Gene signatures were closely linked to the reduced effectiveness of medicine for these patients.

In conclusion, ferroptosis related gene signatures are promising candidates for disease prognosis, and their discovery could lead to novel approaches to the treatment of acute myeloid leukemia.

急性髓系白血病是一种血液系统恶性肿瘤，是成年人中最常见的白血病类型。即便在治疗有效的前提下，
大多数患者的病情在经过一段时间后仍会恶化，只有不到30%的患者能在确诊后存活5年以上。

为了寻找急性髓系白血病新型预后标志物，浙江大学医学院附属第一医院血液科的研究人员利用生物信息
学方法成功建立了一种铁死亡基因风险预后模型。该模型是基于铁死亡相关基因，研究人员发现其中12个
与患者总体生存率密切相关。

根据铁死亡基因风险预后模型，患者被分为高风险组和低风险组，高风险总生存率显著低于低风险组，同
时该预后模型也能预测相关药物的治疗效果和反应。

总而言之，铁死亡基因风险预后模型是预测急性髓系白血病患者预后的有效手段，它的发现将有助于疾病
诊断和治疗的进步。